Open Orphan Share Discussion Threads

[bobsworth] 29/11/2020 13:21

Released : 09 March 2020
RNS Number : 3586F
Open Orphan PLC
09 March 2020

OC43

Open Orphan will utilise common coronavirus strains such as OC43 and 229E which are from the same family of viruses as the newly emerging Covid-19 virus but unlike Covid-19 these common coronaviruses have been widespread in the community for many years and cause only a mild cold-like respiratory illness. Consequently, these common coronaviruses, while closely related to the Covid-19 strain can safely be administered to volunteers in hVIVO's highly controlled quarantine clinic, staffed by a highly experienced medical and scientific team who to date have already safely inoculated over 3,000 volunteers in hVIVO's current range of respiratory virus challenge models



This news follows an announcement on Friday 6 March that the Company had signed a contract with a new client, which is a European Biotech company, for the provision of an RSV human challenge study. This study is projected to deliver £3.2m in revenue, all of which is expected to be recognised in 2020. Furthermore, if that study is successful it is anticipated that an additional follow-on larger pivotal challenge study will commence end Q4 2020, delivering significant further revenue which is expected to be a minimum of £7m.

[pogue] 29/11/2020 12:20

Malcommm
its the long term side effects that worry me challenge study will not address that. That is what the pharma companies are unwilling to take legal responsibility for.

[malcolmmm] 29/11/2020 00:23

Independent Challenge studies are needed otherwise a sizeable number of the population who are not convinced that new vaccines with conflicting results is safe and therefore will not take the jab. Thus the virus wont go away. IMO properly monitored Challenge Studies will go a long way in proving the validity of a vaccine and convincing the undecided who are essential in stopping the spread of the virus.

[gregb] 28/11/2020 20:08

That has been going on for some time now.

[malcolmmm] 28/11/2020 16:46

I see North Korea has been trying to hack AstraZeneca employees offering them jobs etc with viruses (non covid) attached to emails job application forms to try and gain entry into their computers.

[toyin] 28/11/2020 09:42

Talkman save the link below.

[gregb] 28/11/2020 09:40

I mentioned last week that OO were not listed as one of the presenters at the LSE event. It has now been removed from the OO events list. Not long to wait for the next one on the 9th.

[talkman2] 28/11/2020 08:26

Is there another investor presentation/ webinar ( LSE ) on the 2nd December?

[little minx] 28/11/2020 07:38

Might be trades from previous days of the week.

[klosters65] 27/11/2020 22:54

Can someone please explain to me, how come many of the larger trades declared after the market has closed, are at a price less than the lowest bid for the day. If you buy in bulk- does it warrant a discount ?I have level 2.

[owenski] 27/11/2020 18:47

Looking like that's closed slightly above the 'pennant'.

Early days yet but it's deffo above.


free stock charts from uk.advfn.com

[trader_3] 27/11/2020 16:21

Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy

EMA has endorsed a statement by the International Coalition of Medicines Regulatory Authorities (ICMRA) that urges all stakeholders, including vaccines researchers and investigators, academia, regulators and the pharmaceutical industry, to continue COVID-19 vaccine trials beyond the time when the pre-defined cases of COVID-19 disease for final analysis in a trial have been reached. This can provide important additional and more precise information on longer-term safety and efficacy of a vaccine against COVID-19.

‘The work of ICMRA in streamlining regulatory requirements for vaccines through global cooperation has supported the rapid development of COVID-19 vaccines,’ said Emer Cooke, Chair of ICMRA and EMA’s Executive Director. ‘Vaccines will be a key component in overcoming COVID-19, and we must ensure that robust and convincing evidence is being generated to enable the continuous assessment of their benefits and risks.’

[m5] 27/11/2020 15:21

Hoping for a bit more today. Got a bit excited with the early break but should know by now its never done until the close. As we are not at the close yet, it may still happen, if not we are still within the pennant, awaiting a significant move IMHO.

[pogue] 27/11/2020 13:33

Yup NTS agree we were going down a dead end on the ethics discussion so leave it.
Good to have another poster with different perspectives.

[nickthe saint] 27/11/2020 13:10

M5 - cheers

[m5] 27/11/2020 12:57

This breakout goes according to plan, you might not have to wait that long.

[felchandbart] 27/11/2020 12:26

It would be nice to see the share price "bogged down" closer to 50p!! Huge question marks around these vaccines currently - should be playing into our hands.

[m5] 27/11/2020 11:57

NTS, welcome on board. All discussions welcome, but I think your point about getting bogged down is a very fair one.

[nickthe saint] 27/11/2020 11:45

Morning all,

Trout - good to hear re last years Pneumo Vax :-)

Marvel - Thank you for a warm welcome.

Pogue - thanks for your info but I dont think I stated that Challenge studies were the only place that the Hippocratic Oath might come in to play. If thats how you read it sorry for any confusion. What I was trying to clarify is that there IS Def an ethical debate about Challenge Studies - Cathal even says that too on the odd occassion. The ethical debate centres around the "do no harm". It is a debate that I lean on the side of "yes challenge studies in controlled settings should be utilised".

Am happy to leave that topic now as I had intended to clarify some of the situatiuon for those whoi maybe havent had the incite that I and others have. Lets try and move the discussion on from that.

I liken vaccine development to injecting people with Strawberry milkshake. In its self it isnt a disease or virus but it might do some harm to some people, but you would inject them in a trial if you thought it might prevent alcoholism. If you injected them with alcohol (which is poisonous in sufficient quantities to all of us) but at a small level of ml in the hope that it cures alcoholism then in theory you are doing a bit of potential harm. If you inject someone with Covid you def know you are doing some harm (albeit perhaps ina a mild form).

I have a lot to contribute to the debate but I dont want any of us to get bogged down in minute detail - not good for our mental well being.

Pierre - you are correct when you refer to the intention to do harm.

Best regards to all.

NTS

[trader_3] 27/11/2020 11:39

hVIVO Consortium & Leiden University

'hVIVO is leading a consortium, on behalf of HIC-Vac, an international network of researchers who are developing human infection challenge (HIC) studies to accelerate the development of vaccines against pathogens, and the Wellcome Trust, to generate regulatory style guidelines on the manufacture of human challenge agents for subsequent use in controlled human infection studies (CHIM).'

Meta Roestenberg
Organisation Lead
Leiden University Medical Center, Department of Parasitology

Angela Van Diepen
Scientific Adviser Role
Leiden University Medical Center, Department of Parasitology

hxxps://hvivo.com/aboutus/clinical-trial-consortium/

[m5] 27/11/2020 10:39

Like this price action this morning. Its playing out so far. I think we could be in for a very decent move. IMHO,DYOR.

[trader_3] 27/11/2020 10:29

Four reasons why we need multiple vaccines for Covid-19

hxxps://wellcome.org/news/four-reasons-why-we-need-multiple-vaccines-covid-19?utm_source=twitter&;utm_medium=o-wellcome

Apologies if previously posted.